About this Journal Submit a Manuscript Table of Contents
Scientifica
Volume 2013 (2013), Article ID 857519, 19 pages
http://dx.doi.org/10.1155/2013/857519
Review Article

Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management

Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue, Room 555, Pittsburgh, PA 15232, USA

Received 6 December 2012; Accepted 10 January 2013

Academic Editors: D. Jun and M. H. Manjili

Copyright © 2013 Ahmad Tarhini. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [13 citations]

The following is the list of published articles that have cited the current article.

  • Brian A. Baldo, “Adverse events to monoclonal antibodies used for cancer therapy Focus on hypersensitivity responses,” Oncoimmunology, vol. 2, no. 10, 2013. View at Publisher · View at Google Scholar
  • Ahmad A. Tarhini, Howard Edington, Lisa H. Butterfield, Yan Lin, Yongli Shuai, Hussein Tawbi, Cindy Sander, Yan Yin, Matthew Holtzman, Jonas Johnson, Uma N. M. Rao, and John M. Kirkwood, “Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab,” Plos One, vol. 9, no. 2, 2014. View at Publisher · View at Google Scholar
  • Lawrence Steinman, “Conflicting consequences of immunity to cancer versus autoimmunity to neurons: Insights from paraneoplastic disease,” European Journal of Immunology, vol. 44, no. 11, pp. 3201–3205, 2014. View at Publisher · View at Google Scholar
  • Kara M. De Felice, Arjun Gupta, Sagar Rakshit, Sahil Khanna, Lisa A. Kottschade, Heidi D. Finnes, Konstantinos A. Papadakis, Edward V. Loftus, Laura E. Raffals, and Svetomir N. Markovic, “Ipilimumab-induced colitis in patients with metastatic melanoma,” Melanoma Research, vol. 25, no. 4, pp. 321–327, 2015. View at Publisher · View at Google Scholar
  • Shannon K. Quirk, Anna K. Shure, and Devendra K. Agrawal, “Immune-mediated Adverse Effects of Anti-CTLA-4 Antibody Therapy in Metastatic Melanoma,” Translational Research, 2015. View at Publisher · View at Google Scholar
  • P. B. Araujo, M. C. A. Coelho, M. Arruda, M. R. Gadelha, and L. V. Neto, “Ipilimumab-induced hypophysitis: review of the literature,” Journal of Endocrinological Investigation, 2015. View at Publisher · View at Google Scholar
  • Stephanie A. Howard, Michael H. Rosenthal, Jyothi P. Jagannathan, Katherine M. Krajewski, Atul B. Shinagare, Nikhil H. Ramaiya, and Sree Harsha Tirumani, “Beyond the Vascular Endothelial Growth Factor Axis: Update on Role of Imaging in Nonantiangiogenic Molecular Targeted Therapies in Oncology,” American Journal Of Roentgenology, vol. 204, no. 5, pp. 919–932, 2015. View at Publisher · View at Google Scholar
  • A Covre, S Coral, H Nicolay, G Parisi, C Fazio, F Colizzi, E Fratta, A M Di Giacomo, L Sigalotti, P G Natali, and M Maio, “Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models,” OncoImmunology, vol. 4, no. 8, pp. e1019978, 2015. View at Publisher · View at Google Scholar
  • Crescens Tiu, Carmel Pezaro, Ian D Davis, Mathis Grossmann, and Phillip Parente, “Early recognition of ipilimumab-related autoimmune hypophysitis in patients with metastatic melanoma: Case studies and recommendations for management,” Asia-Pacific Journal of Clinical Oncology, 2015. View at Publisher · View at Google Scholar
  • Gwilym J. Webb, and David H. Adams, “Modeling idiosyncrasy: A novel animal model of drug-induced liver injury,” Hepatology, 2015. View at Publisher · View at Google Scholar
  • Evangelia Papavasileiou, Sashank Prasad, Suzanne K. Freitag, Lucia Sobrin, and Ann-Marie Lobo, “Ipilimumab-induced Ocular and Orbital Inflammation—A Case Series and Review of the Literature,” Ocular Immunology & Inflammation, pp. 1–7, 2015. View at Publisher · View at Google Scholar
  • S. Martin, A. M. Dudek-Peric, H. Maes, A. D. Garg, M. Gabrysiak, S. Demirsoy, J. V. Swinnen, and P. Agostinis, “Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells,” Biochemical Pharmacology, vol. 93, no. 3, pp. 290–304, 2015. View at Publisher · View at Google Scholar
  • T. Stahl, and C. Loquai, “Therapienebenwirkungen und Nachsorge bei malignem Melanom,” Der Radiologe, 2015. View at Publisher · View at Google Scholar